Quantinno Capital Management LP
Position in DSGN — Design Therapeutics, Inc.
CIK 1759654
NEW YORK, NY
Position in DSGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$150,321
New position
Shares Held
14,128
first reported quarter
Ownership
0.023%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Quantinno Capital Management LP holds $387,171,373 across 157 Biotechnology names. DSGN ranks #146 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
126,604 | $56,533,750 | |
| 2 | TECH |
BIO-TECHNE Corp
|
814,322 | $42,556,467 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
48,251 | $37,280,652 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
191,286 | $36,162,618 | |
| 5 | RPRX |
Royalty Pharma plc
|
382,571 | $18,351,930 | |
| 6 | INCY |
Incyte Corp
|
158,226 | $14,892,231 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
33,850 | $11,199,949 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
138,547 | $8,954,292 |
All Filings in DSGN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $150,321 | 14,128 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||